|Slideshows|July 20, 2017

6 Ways to Reduce No-Shows (and Save Lives)

Not just a nuisance, no-shows are an opportunity to turn things around for patients with bipolar disorder, whose treatment adherence hovers around 60%.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

ByAndrew Nguyen, MD, MSc,Ayal Schaffer, MD, FRCPC

November 26th 2025

Lamotrigine: An Update on Its Role in Bipolar Disorder

ByDavid N. Osser, MD

November 14th 2025

Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder

ByLeah Kuntz

October 23rd 2025

FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder

ByLeah Kuntz

October 16th 2025

The Use of Aripiprazole for Bipolar Disorder

ByDavid N. Osser, MD

October 15th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

6 Ways to Reduce No-Shows (and Save Lives)

Newsletter

Related Content

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

Lamotrigine: An Update on Its Role in Bipolar Disorder

Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder

FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder

The Use of Aripiprazole for Bipolar Disorder

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

The Hybrid Model: Humans & Chatbots Working Together

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

The Truth About Insomnia and Melatonin: Natural Does Not Always Mean Harmless

Lithium Reduces Risk of Suicide and Recurrent Episodes of Bipolar and Major Depressive Disorders

New Drug Application Submitted for Centanafidine for Treatment of ADHD